NCT05984537View on ClinicalTrials.gov

A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.

PHASE4RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

January 4, 2026

Conditions
Coronary Microvascular Dysfunction
Interventions
DRUG

Bivalirudin

Participants in the bivalirudin group received a one-time intravenous injection of 0.75 mg/kg during PCI, and then received a continuous intravenous infusion of 1.75 mg/kg/h for 4 hours according to the participants' condition after PCI.

DRUG

standard heparin

Participants in the standard heparin group received a one-time intravenous injection of 50 U/kg of standard heparin during PCI.

Trial Locations (1)

10034

RECRUITING

Peking university first hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER